• Taste dysfunction following radiotherapy to the head and neck: A systematic review. 

  Gunn, L; Gilbert, J; Nenclares, P; Soliman, H; Newbold, K; Bhide, S; Wong, KH; Harrington, K; Nutting, C

  <h4>Background</h4>An intact sense of taste provides pleasure, supports sustenance and alerts the body to toxins. Head and neck cancer (HNC) patients who receive radiotherapy (RT) are high-risk for developing radiation-induced ...
• The role of the SWI/SNF chromatin remodelling complex in the response to DNA double strand breaks. 

  Harrod, A; Lane, KA; Downs, JA

  Mammalian cells possess multiple closely related SWI/SNF chromatin remodelling complexes. These complexes have been implicated in the cellular response to DNA double strand breaks (DSBs). Evidence suggests that SWI/SNF ...
• Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. 

  Vasiliadou, I; Breik, O; Baker, H; Leslie, I; Sim, VR; Hegarty, G; Michaelidou, A; Nathan, K; Hartley, A; Good, J; Sanghera, P; Fong, C; Urbano, TG; Lei, M; Petkar, I; Ferreira, MR; Nutting, C; Wong, KH; Newbold, K; Harrington, K; Bhide, S; Kong, A (2021-03-19)

  Nivolumab is an anti-PD-1 monoclonal antibody currently used as immunotherapy for patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) with evidence of disease progression after platinum-based ...
• Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. 

  Kottke, T; Tonne, J; Evgin, L; Driscoll, CB; van Vloten, J; Jennings, VA; Huff, AL; Zell, B; Thompson, JM; Wongthida, P; Pulido, J; Schuelke, MR; Samson, A; Selby, P; Ilett, E; McNiven, M; Roberts, LR; Borad, MJ; Pandha, H; Harrington, K; Melcher, A; Vile, RG (2021-03-26)

  In our clinical trials of oncolytic vesicular stomatitis virus expressing interferon beta (VSV-IFNβ), several patients achieved initial responses followed by aggressive relapse. We show here that VSV-IFNβ-escape tumors ...
• Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations. 

  Ho, AL; Brana, I; Haddad, R; Bauman, J; Bible, K; Oosting, S; Wong, DJ; Ahn, M-J; Boni, V; Even, C; Fayette, J; Flor, MJ; Harrington, K; Kim, S-B; Licitra, L; Nixon, I; Saba, NF; Hackenberg, S; Specenier, P; Worden, F; Balsara, B; Leoni, M; Martell, B; Scholz, C; Gualberto, A (2021-03-22)

  <h4>Purpose</h4>Mutations in the <i>HRAS</i> (m<i>HRAS</i>) proto-oncogene occur in 4%-8% of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Tipifarnib is a farnesyltransferase ...
• A commercial antibody to the human condensin II subunit NCAPH2 cross-reacts with a SWI/SNF complex component. 

  Cutts, EE; Taylor, GC; Pardo, M; Yu, L; Wills, JC; Choudhary, JS; Vannini, A; Wood, AJ (2021-01-13)

  Condensin complexes compact and disentangle chromosomes in preparation for cell division. Commercially available antibodies raised against condensin subunits have been widely used to characterise their cellular interactome. ...
• Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. 

  Vaclova, T; Grazini, U; Ward, L; O'Neill, D; Markovets, A; Huang, X; Chmielecki, J; Hartmaier, R; Thress, KS; Smith, PD; Barrett, JC; Downward, J; de Bruin, EC (2021-03-19)

  Advanced non-small-cell lung cancer (NSCLC) patients with EGFR T790M-positive tumours benefit from osimertinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Here we show that the size of the ...
• Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit. 

  Cojocaru, E; Palahepitiva Gamage, G; Butler, J; Barton, DP; Thway, K; Fisher, C; Messiou, C; Miah, AB; Zaidi, S; Gennatas, S; Benson, C; Huang, P; Jones, RL

  Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiomyosarcoma is the rarest subtype. Primary ovarian leiomyosarcoma has a very poor prognosis, with less than 20% of patients ...
• Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial. 

  Lansu, J; Bovée, JVMG; Braam, P; van Boven, H; Flucke, U; Bonenkamp, JJ; Miah, AB; Zaidi, SH; Thway, K; Bruland, ØS; Baldini, EH; Jebsen, NL; Scholten, AN; van den Ende, PLA; Krol, ADG; Ubbels, JF; van der Hage, JA; van Werkhoven, E; Klomp, HM; van der Graaf, WTA; van Coevorden, F; Schrage, Y; van Houdt, WJ; Haas, RL (2021-01-21)

  <h4>Importance</h4>Currently, preoperative radiotherapy for all soft-tissue sarcomas is identical at a 50-Gy dose level, which can be associated with morbidity, particularly wound complications. The observed clinical ...
• A commercial antibody to the human condensin II subunit NCAPH2 cross-reacts with a SWI/SNF complex component 

  Cutts, E; Taylor, G; Pardo, M; Yu, L; Wills, J; Choudhary, J; Vannini, A; Wood, A (2021-01-13)

  Condensin complexes compact and disentangle chromosomes in preparation for cell division. Commercially available antibodies raised against condensin subunits have been widely used to characterise their cellular interactome. ...
• Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. 

  Quinn, C; Garrison, LP; Pownell, AK; Atkins, MB; de Pouvourville, G; Harrington, K; Ascierto, PA; McEwan, P; Wagner, S; Borrill, J; Wu, E

  Immuno-oncologics (IOs) differ from chemotherapies as they prime the patient's immune system to attack the tumor, rather than directly destroying cancer cells. The IO mechanism of action leads to durable responses and ...
• Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. 

  Harrington, KJ; Soulières, D; Le Tourneau, C; Dinis, J; Licitra, LF; Ahn, M-J; Soria, A; Machiels, J-PH; Mach, N; Mehra, R; Burtness, B; Ellison, MC; Cheng, JD; Chirovsky, DR; Swaby, RF; Cohen, EEW (2020-05-14)

  <h4>Background</h4>Head and neck squamous cell carcinoma (HNSCC) affects health-related quality of life (HRQoL); few treatments have demonstrated clinically meaningful HRQoL benefit. KEYNOTE-040 evaluated pembrolizumab vs ...
• APOBEC and cancer viroimmunotherapy: Thinking the Unthinkable. 

  Vile, RG; Melcher, A; Pandha, H; Harrington, KJ; Pulido, JS (2021-02-08)

  The apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC) family protects against infection by degrading incoming viral genomes through cytosine deamination. Here, we review how the potential to unleash these ...
• Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial. 

  Burtness, B; Haddad, R; Dinis, J; Trigo, J; Yokota, T; de Souza Viana, L; Romanov, I; Vermorken, J; Bourhis, J; Tahara, M; Martins Segalla, JG; Psyrri, A; Vasilevskaya, I; Nangia, CS; Chaves-Conde, M; Kiyota, N; Homma, A; Holeckova, P; Del Campo, JM; Asarawala, N; Nicolau, UR; Rauch, D; Even, C; Wang, B; Gibson, N; Ehrnrooth, E; Harrington, K; Cohen, EEW; LUX-Head & Neck 2 investigators (2019-06-13)

  <h4>Importance</h4>Locoregionally advanced head and neck squamous cell cancer (HNSCC) is treated curatively; however, risk of recurrence remains high among some patients. The ERBB family blocker afatinib has shown efficacy ...
• International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. 

  Lee, AW; Ng, WT; Pan, JJ; Chiang, C-L; Poh, SS; Choi, HC; Ahn, YC; AlHussain, H; Corry, J; Grau, C; Grégoire, V; Harrington, KJ; Hu, CS; Kwong, DL; Langendijk, JA; Le, QT; Lee, NY; Lin, JC; Lu, TX; Mendenhall, WM; O'Sullivan, B; Ozyar, E; Peters, LJ; Rosenthal, DI; Sanguineti, G; Soong, YL; Tao, Y; Yom, SS; Wee, JT

  <h4>Purpose</h4>The treatment of nasopharyngeal carcinoma requires high radiation doses. The balance of the risks of local recurrence owing to inadequate tumor coverage versus the potential damage to the adjacent organs ...
• The transformation of radiation oncology using real-time magnetic resonance guidance: A review. 

  Hall, WA; Paulson, ES; van der Heide, UA; Fuller, CD; Raaymakers, BW; Lagendijk, JJW; Li, XA; Jaffray, DA; Dawson, LA; Erickson, B; Verheij, M; Harrington, KJ; Sahgal, A; Lee, P; Parikh, PJ; Bassetti, MF; Robinson, CG; Minsky, BD; Choudhury, A; Tersteeg, RJHA; Schultz, CJ; MR Linac Atlantic Consortium and the ViewRay C2T2 Research Consortium

  Radiation therapy (RT) is an essential component of effective cancer care and is used across nearly all cancer types. The delivery of RT is becoming more precise through rapid advances in both computing and imaging. The ...
• Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. 

  Rodriguez-Ruiz, ME; Vitale, I; Harrington, KJ; Melero, I; Galluzzi, L

  Therapeutic irradiation of the tumor microenvironment causes differential activation of pro-survival and pro-death pathways in malignant, stromal, endothelial and immune cells, hence causing a profound cellular and biological ...
• Transoral robotic surgery for recurrent cancers of the upper aerodigestive tract-Systematic review and meta-analysis. 

  Hardman, J; Liu, Z; Brady, G; Roe, J; Kerawala, C; Riva, F; Clarke, P; Kim, D; Bhide, S; Nutting, C; Harrington, K; Paleri, V

  <h4>Background</h4>Transoral robotic surgery (TORS) for recurrent head and neck (H&N) cancer is an emerging but relatively infrequent procedure.<h4>Methods</h4>Systematic review and meta-analysis of studies reporting ...
• Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors. 

  Annels, NE; Simpson, GR; Denyer, M; Arif, M; Coffey, M; Melcher, A; Harrington, K; Vile, R; Pandha, H

  Prostate cancers are considered "cold" tumors characterized by minimal T cell infiltrates, absence of a type I interferon (IFN) signature, and the presence of immunosuppressive cells. This non-inflamed phenotype is likely ...
• The role of spread through air spaces (STAS) in lung adenocarcinoma prognosis and therapeutic decision making. 

  Toki, MI; Harrington, K; Syrigos, KN

  Spread through air spaces (STAS) was included as a novel pattern of invasion in lung adenocarcinoma by the World Health Organization in 2015. Since then, multiple studies have investigated the association of STAS with ...

View more